Skip to main content

Table 1 Demographic and clinicopathological features of the 47 analyzed metastatic breast cancer patients

From: In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis

Age
 Median (range) 62 (36–82)
 < 70 years 36 (77 %)
 ≥ 70 years 11 (23 %)
ECOG PS, n (%)  
 0 29 (62 %)
 1 14 (29 %)
 2 4 (9 %)
Immunophenotype, n (%)
 Luminal-like 25 (54 %)
 HER2-positive 11 (23 %)
 Triple negative 11 (23 %)
Histotype, n (%)
 Ductal 38 (84 %)
 Lobular 7 (16 %)
Metastatic sites,a n (%)
 Bone 29 (62 %)
 Liver 22 (47 %)
 Lung 16 (34 %)
 CNS 3 (6 %)
Number of metastatic sites, n (%)
 1 16 (34 %)
 ≥ 2 31 (66 %)
Number of previous lines, n (%)
 0 15 (32 %)
 1 9 (19 %)
 ≥ 2 23 (49 %)
Type of treatments received, n (%)
 Chemotherapy 33 (70 %)
 Endocrine therapy 6 (13 %)
 Chemotherapy and endocrine therapy 5 (11 %)
 Palliative care 2 (6 %)
 Anti-HER2 targeted therapy 12 (26 %)
  1. aPatients may have more than one site involved
  2. ECOG PS Eastern Cooperative Oncology Group Performance Status, CNS central nervous system, HER2 human epidermal growth factor receptor 2